Mar. 26 at 5:48 PM
$TVGN Here is the calculation based on the
$70 million in projected revenue (
$50M from Apozeal +
$20M from the new CRO):
1. Applying the Sector Multiple (P/S Ratio)
In the high-growth biotech and AI sector, a conservative multiple is 5x to 7x sales.
Projected Revenue:
$70,000,000.
Estimated Valuation (Market Cap):
$70M x 5 =
$350 million.
2. Target Price
Currently, Tevogen has a market cap of only
$22.5 million (with the stock at
$5.15). If the market values it at those
$350 million:
Upside Potential: The valuation would need to multiply by 15.5 times.
Estimated Target Price:
$5.15 x 15.5 =
$79.80 USD per share.
3. The "Microsoft AI" Factor (Optimistic Scenario)
If the market decides to value Tevogen not just as a pharmaceutical company, but as a tech/AI company (where multiples can reach 15x or 20x sales):
Valuation:
$70M x 15 =
$1.05 Billion (Unicorn status).
Target Price: It could exceed
$150.00 USD, returning to its psychological historical highs.
